Table 2 Response and follow-up of gouty arthritis patients receiving anakinra.
From: Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases
Follow-up characteristics | Anakinra for ≤3 days Number = 23 | Anakinra for >3 days Number = 17 |
|---|---|---|
Response to anakinra, number (%) | ||
Good | 20 (87%) | 16 (94%) |
Partial | 2 (9%) | 0 (0%) |
No response | 1 (4%) | 1 (6%) |
Follow-up duration, months, median (IQR) | 6.0 (1.5 to 14.0) | 8.0 (3.0 to 13.0) |
Prevention of relapse, number (%) | ||
Total | 17 (74%)a | 13 (76%) |
Low-dose colchicine | 16 (89%) | 7 (54%) |
NSAIDs | 3 (17%) | 1 (8%) |
Steroids | 1 (6%) | 2 (15%) |
Anakinra | 1 (6%) | 9 (69%) |
Relapse, number (%) | 6 (26%) | 7 (41%) |
Delay to relapse, days, median (IQR) | 15.0 (6.0 to 26.3) | 60.0 (12.5 to 125.0) |
Skin reaction | None | None |
Infectious events under anakinra therapy (delay after starting anakinra) | H1N1 infection (1 day) | Staphylococcus aureus tophus (1 year) S. aureus tophus (4 years) S. aureus lung abcess (1 month) Erysipela of the leg (2 months) Streptococcus B urinary tract infection (1 month) S. aureus knee arthritis (1 year) |